Using T cells to target malignant brain tumors

using t cells to target malignant brain tumors

Sumary of Using T cells to target malignant brain tumors:

  • Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University’s Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.
  • However, a basic requirement for this kind of targeted immunotherapy is to identify target molecules that are found exclusively on the tumor cells and are recognized by the immune system.
  • Using an experimental mouse model, Bunse and his team have now demonstrated for the first time that transgenic T cells targeting tumor neoepitopes can be used to treat gliomas.
  • They subsequently transferred the isolated TCR gene to cells and were thus able to grow large amounts of “transgenic” T cells in a petri dish that all had an identical, highly active TCR targeting the CIC neoepitope.
  • In order to study their efficacy, the researchers injected the transgenic cells directly into the brain ventricles of glioma-bearing mice.
  • In combination with radiotherapy, the T cell therapy led to glioma rejection in some of the animals.
  • “Here we have shown for the first time in an experimental model that a neoantigen-specific TCR-transgenic cell therapy can be effective against gliomas,” explained Michael Kilian, first author of the study.
  • “These kinds of neoepitope-specific TCR-transgenic T cells could be used in future in cancer patients who cannot be treated using CAR T cells,” he added.

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.